---
search:
  boost: 3
---

# Endometriosis

This is a subcategory of Endocrine Agents.

## Decision Trees

- [Endocrine - Endometriosis - Danazol, Depo-Subq Provera 104, Lupaneta Pack, Orilissa, Zoladex](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQ0hQOE1POEJWSVpIRERFUEpRM0JEVTFIWSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Endocrine - Endometriosis - Lupron Depot 3.75mg, 11.25mg](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMllJSlBUQjdNWDROWjdZRVRGRjNCNzRMQiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Endocrine - Endometriosis - Myfembree](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQTQxR1JDNTFIMVdKMk1MQ01LN1pDRTRZQSQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Endocrine - Endometriosis - Synarel](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURUFSTFVPVkcyR00yUkI2QkIwWFJMME9JMyQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                    | Generic Name                                                      |         Quantity          |        Time (Days)        |
| :------------------------------------------- | :---------------------------------------------------------------- | :-----------------------: | :-----------------------: |
| Danazol <sup>ST</sup>                        |                                                                   |                           |                           |
| Depo-Subq Provera 104 <sup>ST</sup>          |                                                                   |                           |                           |
| Lupaneta Pack <sup>ST</sup>                  |                                                                   |                           |                           |
| Lupron Depot <sup>QL ST</sup> 3.75, 11.25 MG | Leuprolide Acetate for Depot IM Susp 3.75 MG & 11.25 MG           | Determined pursuant to PA | Determined pursuant to PA |
| Myfembree <sup>QL ST</sup>                   | Relugolix / Estradiol / Norethindrone Acetate Tab (all strengths) | Determined pusuant to PA  | Determined pursuant to PA |
| Orilissa <sup>ST</sup>                       |                                                                   |                           |                           |
| Zoladex <sup>ST</sup>                        |                                                                   |                           |                           |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Synarel       |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy 

Step Therapy Approval Criteria

- Must have had an inadequate clinical response of at least ^^84 days^^ with at least ^^one preferred^^ NSAID and ^^one preferred^^ oral contraceptive 

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^84 days^^ with at least ^^one preferred^^ NSAID, ^^one preferred^^ oral contraceptive, **AND** ^^one preferred^^ step-therapy drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com/:w:/g/personal/rachel_carpenter_gainwelltechnologies_com/EWN_d80YfxNHjWqwQ77mMfUB4JILmO6MEqvBSxlBn5-uug?e=mdkuXX46&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} </br>
[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=57){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=21){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
